

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.\*

*(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)  
(Stock Code: 01099)*

## ANNOUNCEMENT CHANGE OF DIRECTORS

### PROPOSED APPOINTMENT OF DIRECTORS

The board (the “**Board**”) of directors (the “**Directors**”) of Sinopharm Group Co. Ltd. (the “**Company**”) hereby announces that on 8 January 2025, it resolved to propose to appoint Mr. Sun Jinglin (“**Mr. Sun**”) as an executive Director, and to propose to appoint each of Mr. Hu Ligang (“**Mr. Hu**”), Mr. Zu Jing (“**Mr. Zu**”) and Mr. Xing Yonggang (“**Mr. Xing**”) as a non-executive Director (the “**Proposed Appointment of Directors**”).

The above Proposed Appointment of Directors was proposed by the nomination committee of the Board (the “**Nomination Committee**”) according to the nomination procedures for Directors of the Company and based on the needs of the Company and has submitted to the Board for review after considering the Director candidates’ relevant qualifications by the Nomination Committee, and will then be submitted by the Board to the extraordinary general meeting for final approval.

In accordance with the articles of association of the Company (the “**Articles of Association**”), the above Proposed Appointment of Directors is subject to the approval by the shareholders of the Company (the “**Shareholders**”) at the extraordinary general meeting of the Company.

Upon the approval of the above Proposed Appointment of Directors by the Shareholders, the Company will enter into a service contract with each of them, respectively. The term of office of each of them as a Director will commence from the date of approval by the Shareholders and end on the expiry of the term of the current session of the Board. Pursuant to the Articles of Association, each of them will be subject to retirement by rotation and re-election upon the expiry of his term of office.

\* *The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*

The remuneration of each of them for serving as a Director will be determined by the Board according to the authorisation granted at the general meeting of the Company and in accordance with the Company's remuneration standard regarding Directors implemented from time to time. According to the Company's current remuneration standard, executive Directors will receive remuneration based on the performance appraisal, incentive measures and annual salary standard settlement, and non-executive Directors will not receive any remuneration from the Company.

## **BIOGRAPHIES OF MR. SUN, MR. HU, MR. ZU AND MR. XING**

**Mr. Sun Jinglin**, aged 47, is a deputy secretary of Party Committee of the Company. Mr. Sun is a PhD candidate, associate chief pharmacist and practicing pharmacist. Mr. Sun previously served as an analyst and a supervisor in the physical and chemical laboratory, and a quality control manager in Beijing Novartis Pharma Co., Ltd., a quality manager in Baxter Healthcare (Tianjin) Co., Ltd., a director of the Inspection Division 2 of the Center for Drug Certification and Management of the State Food and Drug Administration (國家食品藥品監督管理局), a deputy director of the Center for Food and Drug Inspection and a deputy director of the Department of Drug and Cosmetics Supervision of the China Food and Drug Administration (國家食品藥品監督管理總局) and a convenor of the Office for Assessment of the National Regulatory System of Vaccines in the Department of Policies and Regulations of the National Medical Products Administration. Mr. Sun served as the vice president of China National Biotec Group Company Ltd., and has served as a director of Beijing Tiantan Biological Products Corporation Limited (listed on Shanghai Stock Exchange, stock code: 600161) ("**BTBP**") since May 2023. Mr. Sun has served as a deputy secretary of Party Committee of the Company since October 2024.

**Mr. Hu Ligang**, aged 50, is a holder of master's degree in professional accountancy, a principal senior accountant and a PRC certified public accountant (non-practicing member). Mr. Hu previously served as the supervisor and the deputy director of finance department of China National Medicines Corporation Ltd. (listed on Shanghai Stock Exchange, stock code: 600511) ("**SINOPHARM (CNCM LTD)**"), the head of the finance department of the Company, the general manager of financial management centre and a director of the finance department of China National Biotec Group Co., Ltd., the financial director of China National Scientific Instruments and Materials Co., Ltd., and the secretary of the board of directors and the financial director of China National Biotec Group Co., Ltd. Mr. Hu has served as a director of BTBP from November 2015 to November 2024, and the deputy director (in charge of the work) of the operation management department (safety, environmental protection and quality management division) of China National Pharmaceutical Group Co., Ltd. ("**CNPGC**") since August 2024. Mr. Hu is currently also a director of Sinopharm Group Finance Co., Ltd.

**Mr. Zu Jing**, aged 54, is a holder of bachelor's degree in economics and a senior accountant. Mr. Zu previously served as the deputy general manager of the finance department of China National Service Corporation For Chinese Personnel Working Aboard, the deputy general manager and the financial director of Zhongfu Jiayuan Trade Co. (中服嘉遠貿易公司), the general manager of the finance department, the deputy financial director and the financial director of China Sinopharm International Corporation, the financial director of Shanghai Shyndec Pharmaceutical Co., Ltd. (listed on Shanghai

Stock Exchange, stock code: 600420) (“SSPC”), and the director of the international cooperation department of CNPGC. Mr. Zu has served as a full-time external director of CNPGC since October 2024.

**Mr. Xing Yonggang**, aged 48, is a holder of doctor’s degree in law, a senior economist and a solicitor. Mr. Xing previously served as a cadre of SINOPHARM (CNCM LTD), the business supervisor and a senior business supervisor of the office and the legal affairs department, an assistant to director, the deputy director and the director of the legal affairs department of CNPGC, the secretary of the discipline inspection commission of China National Biotec Group Co., Ltd., the deputy general manager and the general legal counsel of China National Pharmaceutical Investment Co., Ltd., and the chairman of the board of supervisors of SSPC. Mr. Xing has served as a full-time external director of CNPGC since October 2024.

Save as disclosed above, as at the date of this announcement, Mr. Sun, Mr. Hu, Mr. Zu and Mr. Xing did not have any relationship with any Director, senior management or substantial or controlling Shareholder of the Company, or have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, as at the date of this announcement, Mr. Sun, Mr. Hu, Mr. Zu and Mr. Xing did not hold any other positions in the Company or any of its subsidiaries, or any directorship in other listed companies in the last three years.

Save as disclosed above, the Company is not aware of any other matter that needs to be brought to the attention of the Shareholders or any matter in relation to the Proposed Appointment of Directors that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

A circular containing, among other things, details of the Proposed Appointment of Directors and a notice of the extraordinary general meeting of the Company will be despatched to the Shareholders on or around 20 January 2025 according to the manner in which the Shareholders have elected to receive corporate communications.

## **RESIGNATION OF DIRECTORS**

The Board hereby announces that, due to work needs, Mr. Wang Kan and Mr. Wang Peng have tendered their resignation as non-executive Directors to the Board on 8 January 2025. The above resignations will take immediate effect.

Both Mr. Wang Kan and Mr. Wang Peng have confirmed that they have no disagreement with the Board and there is no other matter relating to their resignations that needs to be brought to the attention of the Shareholders and the creditors.

During their term of office, Mr. Wang Kan and Mr. Wang Peng diligently and faithfully performed their duties. The Board would like to take this opportunity to express its sincere gratitude to their contribution to the sustainable and stable development and the continuous improvement of the corporate governance level of the Company.

By order of the Board  
**Sinopharm Group Co. Ltd.**  
**Zhao Bingxiang**  
*Chairman*

Shanghai, the PRC  
8 January 2025

*As at the date of this announcement, the executive director of the Company is Mr. Lian Wanyong; the non-executive directors of the Company are Mr. Zhao Bingxiang, Mr. Chen Qiyu, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao.*